Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Operations (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash from Operations for 4 consecutive years, with 14149000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 52.85% to 14149000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 103757000.0, a 32.83% decrease, with the full-year FY2025 number at 103757000.0, down 32.83% from a year prior.
  • Cash from Operations was 14149000.0 for Q4 2025 at Day One Biopharmaceuticals, down from 5805000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 50753000.0 in Q3 2024 to a low of 58997000.0 in Q1 2025.
  • A 4-year average of 27412312.5 and a median of 29897500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 236.93% in 2024, then plummeted 111.44% in 2025.
  • Day One Biopharmaceuticals' Cash from Operations stood at 35310000.0 in 2022, then fell by 17.17% to 41372000.0 in 2023, then grew by 27.47% to 30008000.0 in 2024, then surged by 52.85% to 14149000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Cash from Operations are 14149000.0 (Q4 2025), 5805000.0 (Q3 2025), and 24806000.0 (Q2 2025).